Acrx stock forecast.

Based on 4 Wall Street analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $21.67 with a high forecast of $47.00 and a low forecast of $8.00. The average price target represents a 452.81% change from the last price of $3.92. Highest Price Target $47.00. Average Price Target $21.67.

Acrx stock forecast. Things To Know About Acrx stock forecast.

Dec 1, 2023 · Vince Angotti. AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. 12/31/2023. Next Earnings (Estimated) +423.4%. $-26,640,000.00.ACRX Stock Forecast. While there’s much to be desired from the market after this year, analysts remain bullish. Most recently, Cantor Fitzgerald adjusted its rating to $4 but maintained an Overweight rating. Based on current trading levels, that target sits 615% higher right now.By Thomas Yeung and InvestorPlace Earnings Nov 8, 2023, 1:17 pm EST. ContextLogic ( WISH) stock rose more than 20% post Q3 earnings release. The company reported a 52% drop in year-over-year ...

Based on 7 Wall Street analysts offering 12 month price targets for Applied Digital Corporation in the last 3 months. The average price target is $15.25 with a high forecast of $19.00 and a low forecast of $12.00.

Based on 7 Wall Street analysts offering 12 month price targets for Applied Digital Corporation in the last 3 months. The average price target is $15.25 with a high forecast of $19.00 and a low forecast of $12.00.

A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...Find out why ACRX stock is a Hold. AcelRx Pharmaceuticals raised capital in December 2022, ... Management outlook to 2023 provided at the March 30, 2023 Earnings Call for fiscal 2022.However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0 between high and low, or 0%. For the last week the stock has had daily average volatility of 0%. Our recommended stop-loss: $0.0268 (-4.00%) (This stock has low daily movements and this gives low risk. There is a sell ...View AcelRx Pharmaceuticals, Inc ACRX investment & stock information. Get the latest AcelRx Pharmaceuticals, Inc ACRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

SRNE Stock 12 Months Forecast. Based on 2 Wall Street analysts offering 12 month price targets for Sorrento Therapeutics in the last 3 months. The average price target is $13.00 with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 4130.39% change from the last price of $0.31.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE ...

1 Wall Street research analysts have issued 1-year price targets for Acurx Pharmaceuticals' stock. Their ACXP share price targets range from $13.00 to $13.00. On average, they predict the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price.May 9, 2023 · ACRX competes with other companies such as ATXI, PTIX, and PBLA. On May 9, 2023, ATXI stock remained unchanged, while PTIX stock increased by 2.06%. In contrast, PBLA stock decreased by 21.71%. ACRX is set to report its next earnings on May 11, 2023. ACRX operates in the health technology sector and is involved in the major pharmaceuticals ... Stock Price Forecast. The 2 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.63, with a high estimate of 5.00 and a low estimate of 4.25. The ... Jan 14, 2021 · What's ACRX's stock forecast? By Mohit Oberoi, CFA. Jan. 14 2021, Published 8:19 a.m. ET. Source: Unsplash. AcelRx (ACRX) stock made a new 52-week high of $2.12 on Jan. 12. However, the stock fell ... Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Corbus Pharmaceuticals Holdings Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00.1 January 2022 / pennystocks.com / 4 min read Top Penny Stocks To Buy According To Analysts & Targets Up To 615%Acelrx Pharmaceuticals Stock Forecast, "ACRX" Share Price Prediction Charts Is "Acelrx Pharmaceuticals Inc" a Good Investment? Current price today: 0.640 USD (+4.015%) …

Stock Price Forecast. The 2 analysts offering 12-month price forecasts for NovaBay Pharmaceuticals Inc have a median target of 6.65, with a high estimate of 9.50 and a low estimate of 3.80. The ...Find the latest AcelRx Pharmaceuticals Inc (ACRX) stock forecast, 12-month price target, predictions and analyst recommendations.Track Acelrx Pharmaceuticals Inc (ACRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAcelRx Pharmaceuticals is forecast to grow earnings and revenue by 11.4% and 63.5% per annum respectively while EPS is expected to grow by 33.4% per annum.Future criteria checks 1/6. Acerinox is forecast to grow earnings and revenue by 14% and 1.9% per annum respectively. EPS is expected to grow by 14% per annum. Return on equity is forecast to be 11.2% in 3 years.Based on 4 Wall Street analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $21.67 with a high forecast of $47.00 and a low forecast of $8.00. The average price target represents a 452.81% change from the last price of $3.92. Highest Price Target $47.00. Average Price Target $21.67.

May 15, 2023 · Earnings announcement* for ACRX: May 15, 2023. AcelRx Pharmaceuticals, Inc. is estimated to report earnings on 05/15/2023. The upcoming earnings date is derived from an algorithm based on a ...

Stock Price Forecast The 1 analysts offering 12-month price forecasts for Iterum Therapeutics PLC have a median target of 15.00, with a high estimate of 15.00 and a low estimate of 15.00.AcelRx Pharmaceuticals, Inc. Common Stock (ACRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.SmartAssetPaid Partner. Find real-time CTMX - CytomX Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Which healthcare penny stocks should the risk-tolerant crowd have on their radar right now? AcelRx Pharmaceuticals ( ACRX 3.95%) and Sundial Growers ( SNDL 4.89%) are two potential diamonds in the ...AcelRx Pharmaceuticals (ACRX) Stock Forecast & Price Prediction. Estimation of the future price movement of AcelRx Pharmaceuticals stock, based on various factors such …Find real-time GNPX - Genprex Inc stock quotes, company profile, news and forecasts from CNN Business.Track Acelrx Pharmaceuticals Inc (ACRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAcasti Pharma Inc. (ACST) share price prediction for 2023, 2024, 2025, 2026 and 2027. ACST one year forecast. Acasti Pharma stock monthly and weekly forecasts.

222.96%. Free cash flow. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -4.11M. 12.66%. Get the latest Achieve Life Sciences Inc ...

Data as of 3:59pm ET, 11/21/2023 Financials Profile Forecasts Paid Partner Paid Partner Find real-time ACRX - AcelRx Pharmaceuticals Inc stock quotes, company profile, news and forecasts...

ACRX | Complete AcelRx Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nov 29, 2023 · Iterum Therapeutics plc (NASDAQ:ITRM) released its quarterly earnings results on Friday, November, 12th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $1.80 by $1.50. During the same period last year, the company earned ($5.10) EPS. View the latest news, buy/sell ratings, SEC filings and insider transactions ... Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...See AcelRx Pharmaceuticals, Inc. (ACRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.ACRX Stock USD 1.76 0.08 4.35% AcelRx Pharmaceuticals stock price prediction is an act of determining the future value of AcelRx Pharmaceuticals shares using few different conventional methods such as EPS estimation , analyst consensus, or …ACRX Stock Forecast. While there’s much to be desired from the market after this year, analysts remain bullish. Most recently, Cantor Fitzgerald adjusted its rating to $4 but maintained an Overweight rating. Based on current trading levels, that target sits 615% higher right now.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Inpixon have a median target of 586,488.00, with a high estimate of 586,488.00 and a low estimate of 586,488.00. The ...Find real-time IMGN - ImmunoGen Inc stock quotes, company profile, news and forecasts from CNN Business.AcelRx Pharmaceuticals ( NASDAQ: ACRX) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue ...Stock Price Forecast. The 12 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 31.00, with a high estimate of 31.26 and a low estimate of 19.00. The median ...

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Marker Therapeutics Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The ...AcelRx Pharmaceuticals (ACRX) Stock Forecast & Price Prediction. Estimation of the future price movement of AcelRx Pharmaceuticals stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions. 1.ACRX is currently rated as a Sucker Stock | Stockopedia. Login Get Started. ... Is there a AcelRx Pharmaceuticals share price forecast for 2023? The analyst consensus target price for shares in AcelRx Pharmaceuticals is $4.12. That is …See AcelRx Pharmaceuticals, Inc. (ACRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Instagram:https://instagram. progressive high risk insuranceforex trading in nigeriavanguard federal money mktomf stock dividend AcelRx Pharmaceuticals ( NASDAQ: ACRX) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue ...Stock Price Forecast The 1 analysts offering 12-month price forecasts for Iterum Therapeutics PLC have a median target of 15.00, with a high estimate of 15.00 and a low estimate of 15.00. home depot possessed pennyspy predictions next week Dec 1, 2023 · AcelRx Pharmaceuticals last issued its earnings data on November 8th, 2023. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The company earned $0.12 million during the quarter. AcelRx Pharmaceuticals has generated ($2.23) earnings per share over the last year ... td ameritrade stock price In 2023 so far, the iShares Biotechnology ETF (IBB) is down 7.5% while the S&P 500 is up more than 14%—but from 2012 to 2015, IBB beat the S&P 500 by more than 3-to-1. Picking the right biotech ...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.